Diagnostic performance of Xpert MTB/RIF Ultra assay with pulmonary and extrapulmonary specimens: a retrospective evaluation in a low-incidence setting in Finland
Clinical Microbiology and Infection · 2026
DOI: 10.1016/j.cmi.2025.09.002 ↗Kurz gefasst
Evaluationsstudie in der Zeitschrift Clinical Microbiology and Infection, 2026. Verfasst von Bruno Luukinen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Microbiology, HUS Diagnostic Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; Department of…. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Tuberculosis, Molecular Diagnostic Techniques. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Filha, Tampereen Tuberkuloosisäätiö, Suomen Tuberkuloosin Vastustamisyhdistyksen Säätiö ry.
Abstract (Originalsprache)
OBJECTIVE: The aim was to evaluate the sensitivity and specificity of the Xpert MTB/RIF Ultra (Xpert Ultra) assay in the detection of extrapulmonary tuberculosis (TB) in comparison to pulmonary TB in a low-incidence setting in the Helsinki capital area of Finland. METHODS: The retrospective analysis included results from 1112 pulmonary and 705 extrapulmonary samples collected between 2018 and 2023, of which 193 and 136 were culture-positive for Mycobacterium tuberculosis (MTB), respectively. Xpert Ultra results were compared with mycobacterial culture. PCR-positive and culture-negative cases were separately compared with available clinical data (composite reference standard, CRS). RESULTS: Compared with culture, Xpert Ultra demonstrated 95.3% sensitivity (95% CI, 91.3%-97.7%) and 94.5% specificity (95% CI, 92.8%-95.8%) with pulmonary samples, 47.1% (95% CI, 26.2%-69.0%) and 96.7% (95% CI, 93.8%-98.4%) with pleural fluid, 100% (95% CI, 86.9%-100%) and 81.8% (95% CI, 72.4%-88.6%) with tissue, 96.6% (95% CI, 81.4%-100%) and 75.0% (95% CI, 62.2%-84.6%) with pus, and 95.1% (95% CI, 83.0%-99.5%) and 67.5% (95% CI, 51.9%-80.0%) with lymph node samples, respectively. Other, less common sample types were also included. When CRS was also considered, specificity exceeded 93% for all sample types. Sensitivity was 100% with both smear-positive pulmonary and smear-positive extrapulmonary samples. Neither false rifampicin susceptibility testing results nor cross-reactivity with nontuberculous mycobacteria was detected. DISCUSSION: Xpert Ultra detected MTB in lymph node, tissue, and pus samples with high-accuracy comparable with the analysis of pulmonary samples while reducing the time to diagnosis by up to several weeks compared with mycobacterial culture.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Microbiology, HUS Diagnostic Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; Department of Clinical Microbiology, Fimlab laboratories, Tampere, Finland. Electro…
- Department of Clinical Microbiology, HUS Diagnostic Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; Laboratory of Molecular Biology Applied to Mycobacteria, Oswaldo Cruz Institute, Fi…
- Department of Clinical Microbiology, Fimlab laboratories, Tampere, Finland.
- Department of Clinical Microbiology, HUS Diagnostic Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Förderung
- Filha
- Tampereen Tuberkuloosisäätiö
- Suomen Tuberkuloosin Vastustamisyhdistyksen Säätiö ry
- Suomen Kulttuurirahasto
Zitieren
APA
Luukinen, B., Ahava, M., Aittoniemi, J., Miikkulainen-Lahti, T., & Pätäri-Sampo, A. (2026). Diagnostic performance of Xpert MTB/RIF Ultra assay with pulmonary and extrapulmonary specimens: a retrospective evaluation in a low-incidence setting in Finland. Clinical Microbiology and Infection. https://doi.org/10.1016/j.cmi.2025.09.002
Vancouver
Luukinen B, Ahava M, Aittoniemi J, Miikkulainen-Lahti T, Pätäri-Sampo A. Diagnostic performance of Xpert MTB/RIF Ultra assay with pulmonary and extrapulmonary specimens: a retrospective evaluation in a low-incidence setting in Finland. Clinical Microbiology and Infection. 2026. doi:10.1016/j.cmi.2025.09.002
BibTeX
@article{Luukinen2026,
author = {Luukinen, Bruno and Ahava, Maarit and Aittoniemi, Janne and Miikkulainen-Lahti, Terhi and Pätäri-Sampo, Anu},
title = {Diagnostic performance of Xpert MTB/RIF Ultra assay with pulmonary and extrapulmonary specimens: a retrospective evaluation in a low-incidence setting in Finland},
journal = {Clinical Microbiology and Infection},
year = {2026},
doi = {10.1016/j.cmi.2025.09.002}
}
EUVIMED